Please provide your email address to receive an email when new articles are posted on . Eye drops for presbyopia represent a major opportunity for patients, but their reception by eye care ...

Eye care professionals tell Andrew McCarthy-McClean how they prepare patients for presbyopia In 2026, the UK population is projected to reach 70 million. There were around 12.7m people aged 65 and ...

The US Food and Drug Administration has approved a landmark eye drop that uses a combined dose of medication to restore age-related near-sightedness, without the need for surgery, for a longer ...

Yuvezzi is the first FDA-approved dual-agent eye drop for presbyopia, combining carbachol and brimonidine tartrate. Phase III trials showed Yuvezzi significantly improved near visual acuity without ...

Yuvezzi is expected to be available in the second quarter of 2026. The Food and Drug Administration (FDA) has approved Yuvezzi ™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for ...

The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive alternative to glasses or surgery. Phase 3 trials demonstrated superior ...

Although presbyopia is common and expected in people older than 40 years of age, its symptoms are nonspecific (blurred vision, eye strain or headache); therefore, careful consideration of differential ...